Astrazeneca PLC

AstraZeneca PLC is a biopharmaceutical company that develops, manufactures, and commercializes prescription medicines. Its marketed products treat various conditions, including cardiovascular, renal, metabolism, oncology, and rare diseases. The company has offices worldwide and collaborates with Neurimmune AG and BenevolentAI for drug discovery. It was formerly known as Zeneca Group PLC and changed its name to AstraZeneca in 1999.

Overview

Sector

Pharmaceutical

Target Price

63.7 USD

Current Price

79.1 USD

Potential

-19%

Strengths

Current Price to Earnings Ratio (17.29) is lower than the sector mean (81.73).
Price to book ratio (2.98) is lower than the sector mean (8.32).
EV/EBITDA (9.29) is lower than the sector mean (21.51).
EV/EBIT (13.96) is lower than the sector mean.
Price to free cash flow (16.72) is lower than the sector mean.
Strong EBITDA Margin of 28.83%.

Weaknesses

With a depreciation Potential of -18.83%, based on our fundamental analysis, it suggests the stock may be overvalued.

Key Financial Data

Indicator	Value
PER	17.4
EV/EBITDA	9.4
Price/Free Cash Flow'	16.9
ROIC	17.1%
Net Debt/EBITDA	1.5